Drug Development RFP
Funds early-stage drug and device studies with innovative mechanisms for Alzheimer’s, emphasizing robust science, novel approaches, and biomarker-driven proof-of-concept.
Funder: Alzheimer's Drug Discovery Foundation
Due Dates: September 14, 2026: Letter of Intent deadline
Funding Amounts: Up to $5,000,000 per project (multi-year awards; milestone-based payments)
Summary: Supports IND-enabling studies and early-phase clinical trials for novel drugs and devices targeting Alzheimer’s disease, emphasizing innovative mechanisms and combination therapies.
Key Information: Only direct costs are allowed; funding is provided as mission-related investments with return on investment requirements.
Description
This opportunity funds investigational new drug (IND)-enabling studies and early-phase clinical trials for promising pharmacological interventions and devices targeting Alzheimer’s disease and related dementias. The focus is on innovative drug mechanisms and modes of action related to the biology of aging, including combination therapies, disease-modifying and symptomatic agents, and novel, repurposed, or repositioned drugs and devices. Proposals must provide a strong scientific rationale, robust preclinical (and if available, clinical) data, and detailed plans for study design, recruitment, and biomarker-based proof-of-concept. Collaboration is strongly encouraged to ensure comprehensive project execution.
